Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On May 15, 2025, Tiziana Life Sciences announced the publication of a study in the Journal of Clinical Nuclear Medicine, highlighting the potential of intranasal foralumab in treating moderate Alzheimer’s disease. The study demonstrated a significant reduction in microglial activation in a 78-year-old patient, marking the first use of 18F-PBR06-PET in such a case. This finding suggests a promising new avenue for addressing neuroinflammatory conditions, potentially impacting Tiziana’s market position and offering hope for stakeholders seeking innovative treatments for Alzheimer’s disease.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company specializes in immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana’s approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 764,314
Technical Sentiment Signal: Buy
Current Market Cap: $180.6M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue